Patents by Inventor Minakshi Garg

Minakshi Garg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9872873
    Abstract: The present invention relates to a process of preparing a stable pharmaceutical composition of compounds which are susceptible to hydrolysis comprising a. Addition of required quantity of pharmaceutically acceptable lyophilization excipients optionally in Water for Injection in a formulation vessel; b. Addition of organic solvent to form a appropriate proportion of aqueous and organic solvent; c. Maintaining the temperature of the formulation vessel from the range ?5±1° C. to ?5±3° C.; d. Addition of required quantity of compound susceptible to hydrolysis to form a solution and lyophilizing the solution.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: January 23, 2018
    Assignee: Fresenius Kabi Oncology Limited
    Inventors: Dhiraj Khattar, Rajesh Khanna, Sanjay Motwani, Minakshi Garg, Vikas Chandel, Mukti Yadav, Vijay Kumar Kyama, Vikas Bhandari
  • Patent number: 9669048
    Abstract: Described herein are ready to use, non-aqueous pharmaceutical compositions comprising 5-aza-2?-deoxycitidine and at least one aprotic solvent. The pharmaceutical compositions may further comprise at least one protic solvent. Also described are processes for preparing the pharmaceutical compositions and their use for the treatment of patients suffering from myelodysplastic syndromes.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: June 6, 2017
    Assignee: Fresenius Kabi Oncology Limited
    Inventors: Dhiraj Khattar, Rajesh Khanna, Sanjay Motwani, Sunny Chopra, Minakshi Garg
  • Publication number: 20160166593
    Abstract: Described herein are ready to use, non-aqueous pharmaceutical compositions comprising 5-aza-2?-deoxycitidine and at least one aprotic solvent. The pharmaceutical compositions may further comprise at least one protic solvent. Also described are processes for preparing the pharmaceutical compositions and their use for the treatment of patients suffering from myelodysplastic syndromes.
    Type: Application
    Filed: October 24, 2013
    Publication date: June 16, 2016
    Inventors: Dhiraj KHATTAR, Rajesh KHANNA, Sanjay MOTWANI, Sunny CHOPRA, Minakshi GARG
  • Publication number: 20140378407
    Abstract: The present invention relates to a process of preparing a stable pharmaceutical composition of compounds which are susceptible to hydrolysis comprising a. Addition of required quantity of pharmaceutically acceptable lyophilization excipients optionally in Water for Injection in a formulation vessel; b. Addition of organic solvent to form a appropriate proportion of aqueous and organic solvent; c. Maintaining the temperature of the formulation vessel from the range ?5±1° C. to ?5±3° C.; d. Addition of required quantity of compound susceptible to hydrolysis to form a solution and lyophilizing the solution.
    Type: Application
    Filed: March 29, 2012
    Publication date: December 25, 2014
    Applicant: Fresenius Kabi Oncology Limited
    Inventors: Dhiraj Khattar, Rajesh Khanna, Sanjay Motwani, Minakshi Garg, Vikas Chandel, Mukti Yadav, Vijay Kumar Kyama, Vikas Bhandari
  • Publication number: 20090017105
    Abstract: Concentrates or proliposomal compositions of poorly water-soluble drugs and compounds, comprising of one or more membrane forming lipids, a membrane stabilizing agent, in a suitable vehicle, and optionally containing a Polyethylene Glycol (PEG)-coupled phospholipid or a mixture thereof and further, optionally containing pharmaceutically acceptable excipients such as antioxidants, buffering agents, acidifying agents etc. are provided, which have superior long term stability. The concentrates of proliposomal compositions instantly form liposomes of the said poorly water-soluble drugs and compounds on rapid injection to a diluting fluid, the liposomal composition so obtained, characterized by a physical stability more than 24 hours, ?95% drug encapsulation and having a particle size diameter of less than 100 nm. The liposomal compositions so obtained can further be directly administered to patients in need of treatment of the poorly water-soluble drugs and compounds.
    Type: Application
    Filed: March 11, 2008
    Publication date: January 15, 2009
    Inventors: Dhiraj Khattar, Mukesh Kumar, Rama Mukherjee, Anand C. Burman, Minakshi Garg, Manu Jaggi, Anu T. Singh, Anshumali Awasthi